These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 32737030)

  • 1. Endometrial Cancer Molecular Risk Stratification is Equally Prognostic for Endometrioid Ovarian Carcinoma.
    Krämer P; Talhouk A; Brett MA; Chiu DS; Cairns ES; Scheunhage DA; Hammond RFL; Farnell D; Nazeran TM; Grube M; Xia Z; Senz J; Leung S; Feil L; Pasternak J; Dixon K; Hartkopf A; Krämer B; Brucker S; Heitz F; du Bois A; Harter P; Kommoss FKF; Sinn HP; Heublein S; Kommoss F; Vollert HW; Manchanda R; de Kroon CD; Nijman HW; de Bruyn M; Thompson EF; Bashashati A; McAlpine JN; Singh N; Tinker AV; Staebler A; Bosse T; Kommoss S; Köbel M; Anglesio MS
    Clin Cancer Res; 2020 Oct; 26(20):5400-5410. PubMed ID: 32737030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TCGA molecular subgroups of endometrial carcinoma in ovarian endometrioid carcinoma: A quantitative systematic review.
    D'Alessandris N; Travaglino A; Santoro A; Arciuolo D; Scaglione G; Raffone A; Inzani F; Zannoni GF
    Gynecol Oncol; 2021 Nov; 163(2):427-432. PubMed ID: 34446267
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular Classification of Grade 3 Endometrioid Endometrial Cancers Identifies Distinct Prognostic Subgroups.
    Bosse T; Nout RA; McAlpine JN; McConechy MK; Britton H; Hussein YR; Gonzalez C; Ganesan R; Steele JC; Harrison BT; Oliva E; Vidal A; Matias-Guiu X; Abu-Rustum NR; Levine DA; Gilks CB; Soslow RA
    Am J Surg Pathol; 2018 May; 42(5):561-568. PubMed ID: 29505428
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Prognostic Effect of Immune Cell Infiltration Depends on Molecular Subtype in Endometrioid Ovarian Carcinomas.
    Heinze K; Cairns ES; Thornton S; Harris B; Milne K; Grube M; Meyer C; Karnezis AN; Fereday S; Garsed DW; Leung SCY; Chiu DS; Moubarak M; Harter P; Heitz F; McAlpine JN; DeFazio A; Bowtell DDL; Goode EL; Pike M; Ramus SJ; Pearce CL; Staebler A; Köbel M; Kommoss S; Talhouk A; Nelson BH; Anglesio MS
    Clin Cancer Res; 2023 Sep; 29(17):3471-3483. PubMed ID: 37339172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinicopathological and molecular characterisation of 'multiple-classifier' endometrial carcinomas.
    León-Castillo A; Gilvazquez E; Nout R; Smit VT; McAlpine JN; McConechy M; Kommoss S; Brucker SY; Carlson JW; Epstein E; Rau TT; Soslow RA; Ganesan R; Matias-Guiu X; Oliva E; Harrison BT; Church DN; Gilks CB; Bosse T
    J Pathol; 2020 Mar; 250(3):312-322. PubMed ID: 31829447
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy.
    León-Castillo A; de Boer SM; Powell ME; Mileshkin LR; Mackay HJ; Leary A; Nijman HW; Singh N; Pollock PM; Bessette P; Fyles A; Haie-Meder C; Smit VTHBM; Edmondson RJ; Putter H; Kitchener HC; Crosbie EJ; de Bruyn M; Nout RA; Horeweg N; Creutzberg CL; Bosse T;
    J Clin Oncol; 2020 Oct; 38(29):3388-3397. PubMed ID: 32749941
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TCGA molecular classification in endometriosis-associated ovarian carcinomas: Novel data on clear cell carcinoma.
    Similä-Maarala J; Soovares P; Pasanen A; Ahvenainen T; Vahteristo P; Bützow R; Lassus H
    Gynecol Oncol; 2022 Jun; 165(3):577-584. PubMed ID: 35370008
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Variability in endometrial carcinoma pathology practice: opportunities for improvement with molecular classification.
    Thompson EF; Huvila J; Jamieson A; Leung S; Lum A; Offman S; Lytwyn A; Sur ML; Hoang L; Irving J; van der Westhuizen N; Morin C; Bicamumpaka C; Azordegan N; Gougeon F; Ennour-Idrissi K; Senz J; McConechy MK; Aguirre-Hernandez R; Lui V; Kuo C; Bell C; Salisbury T; Lawson J; He E; Wang S; Chiu D; Kean S; Samouëlian V; Salvador S; Gotlieb W; Helpman L; Scott S; Wohlmuth C; Vicus D; Plante M; Talhouk A; Huntsman D; Parra-Herran C; Kinloch M; Grondin K; Gilks CB; McAlpine JN;
    Mod Pathol; 2022 Dec; 35(12):1974-1982. PubMed ID: 36241860
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular subtypes of clear cell carcinoma of the endometrium: Opportunities for prognostic and predictive stratification.
    Kim SR; Cloutier BT; Leung S; Cochrane D; Britton H; Pina A; Storness-Bliss C; Farnell D; Huang L; Shum K; Lum A; Senz J; Lee CH; Gilks CB; Hoang L; McAlpine JN
    Gynecol Oncol; 2020 Jul; 158(1):3-11. PubMed ID: 32331700
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incorporation of molecular characteristics into endometrial cancer management.
    Vermij L; Smit V; Nout R; Bosse T
    Histopathology; 2020 Jan; 76(1):52-63. PubMed ID: 31846532
    [TBL] [Abstract][Full Text] [Related]  

  • 11. "Surface epithelial slackening" pattern in endometrioid carcinoma: A morphological feature for differentiating the POLE mutation-subtype from the no specific molecular profile subtype.
    Kitazono I; Akahane T; Yokoyama S; Kobayashi Y; Togami S; Yanazume S; Tasaki T; Noguchi H; Tabata K; Kobayashi H; Tanimoto A
    Pathol Res Pract; 2023 Jul; 247():154563. PubMed ID: 37229919
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinicopathological and molecular characterization of high-grade endometrial carcinoma with POLE mutation: a single center study.
    Yu S; Sun Z; Zong L; Yan J; Yu M; Chen J; Lu Z
    J Gynecol Oncol; 2022 May; 33(3):e38. PubMed ID: 35320887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular Classification Outperforms Histologic Classification in Prognostication of High-grade Endometrial Carcinomas With Undifferentiated and Sarcomatous Components.
    Hammer PM; Wang A; Vermij L; Zdravkovic S; Heilbroner L; Ryan E; Geisick RLP; Charu V; Longacre TA; Suarez CJ; Ho C; Jenkins TM; Mills AM; Bosse T; Howitt BE
    Am J Surg Pathol; 2024 Aug; 48(8):953-964. PubMed ID: 38780000
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of the TCGA molecular classification in uterine carcinosarcoma.
    Travaglino A; Raffone A; Raimondo D; Arciuolo D; Angelico G; Valente M; Scaglione G; D'alessandris N; Casadio P; Inzani F; Mollo A; Santoro A; Seracchioli R; Franco Zannoni G
    Int J Gynaecol Obstet; 2022 Jul; 158(1):13-20. PubMed ID: 34536971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinicopathological characteristics of multiple-classifier endometrial cancers: a cohort study and systematic review.
    De Vitis LA; Schivardi G; Caruso G; Fumagalli C; Vacirca D; Achilarre MT; Aloisi A; Garbi A; Zanagnolo V; Aletti G; Guerini-Rocco E; Mariani A; Maggioni A; Barberis M; Bogani G; Colombo N; Multinu F; Betella I
    Int J Gynecol Cancer; 2024 Feb; 34(2):229-238. PubMed ID: 38135437
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ATM immunohistochemistry as a potential marker for the differential diagnosis of no specific molecular profile subtype and POLE-mutation subtype endometrioid carcinoma.
    Kitazono I; Kobayashi Y; Akahane T; Yamaguchi T; Yanazume S; Nohara S; Sakamoto I; Tabata K; Tasaki T; Kobayashi H; Tanimoto A
    Pathol Res Pract; 2022 Feb; 230():153743. PubMed ID: 34954471
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic relevance of the molecular classification in high-grade endometrial cancer for patients staged by lymphadenectomy and without adjuvant treatment.
    Leon-Castillo A; Horeweg N; Peters EEM; Rutten T; Ter Haar N; Smit VTHBM; Kroon CD; Boennelycke M; Hogdall E; Hogdall C; Nout RRA; Creutzberg CL; Ortoft G; Bosse T
    Gynecol Oncol; 2022 Mar; 164(3):577-586. PubMed ID: 35078648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endometrial Carcinosarcomas are Almost Exclusively of p53abn Molecular Subtype After Exclusion of Mimics.
    Huvila J; Jamieson A; Pors J; Hoang L; Mirkovic J; Cochrane D; McAlpine JN; Gilks CB
    Int J Gynecol Pathol; 2024 Sep; 43(5):506-514. PubMed ID: 38303106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular-based classification algorithm for endometrial carcinoma categorizes ovarian endometrioid carcinoma into prognostically significant groups.
    Parra-Herran C; Lerner-Ellis J; Xu B; Khalouei S; Bassiouny D; Cesari M; Ismiil N; Nofech-Mozes S
    Mod Pathol; 2017 Dec; 30(12):1748-1759. PubMed ID: 28776572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. p53 immunohistochemistry is an accurate surrogate for TP53 mutational analysis in endometrial carcinoma biopsies.
    Singh N; Piskorz AM; Bosse T; Jimenez-Linan M; Rous B; Brenton JD; Gilks CB; Köbel M
    J Pathol; 2020 Mar; 250(3):336-345. PubMed ID: 31829441
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.